Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients
Ventura-Cots, Meritxell (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Concepción, Mar (Institut d'Investigació Biomèdica Sant Pau)
Arranz-Amo, Jose Antonio
Simón-Talero, Macarena (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Torrens, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Blanco-Grau, Albert (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Fuentes Camps, Inmaculada (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Suñé, Pilar (Hospital Universitari Vall d'Hebron)
Alvarado-Tapias, Edilmar (Institut d'Investigació Biomèdica Sant Pau)
Gely, Cristina (Institut d'Investigació Biomèdica Sant Pau)
Roman, Eva (Institut d'Investigació Biomèdica Sant Pau)
Mínguez, Beatriz (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Soriano, German (Institut d'Investigació Biomèdica Sant Pau)
Genescà Ferrer, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Córdoba Cardona, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Date:	2016
Abstract:	Ornithine phenylacetate (OP) has been proven effective in lowering ammonia plasma levels in animals, and to be well tolerated in cirrhotic patients. A trial to assess OP efficacy in lowering plasma ammonia levels versus placebo in cirrhotic patients after an upper gastrointestinal bleeding was performed. The primary outcome was a decrease in venous plasma ammonia at 24 hours. A total of 38 consecutive cirrhotic patients were enrolled within 24 hours of an upper gastrointestinal bleed. Patients were randomized (1:1) to receive OP (10 g/day) or glucosaline for 5 days. The primary outcome was not achieved. A progressive decrease in ammonia was observed in both groups, being slightly greater in the OP group, with significant differences only at 120 hours. The subanalysis according to Child-Pugh score showed a statistically significant ammonia decrease in Child-Pugh C-treated patients at 36 hours, as well as in the time-normalized area under the curve (TN-AUC) 0-120 hours in the OP group [40. 16 μmol/l (37. 7-42. 6); median (interquartile range) (IQR)] versus placebo group [65. 5 μmol/l (54-126); p = 0. 036]. A decrease in plasma glutamine levels was observed in the treated group compared with the placebo group, and was associated with the appearance of phenylacetylglutamine in urine. Adverse-event frequency was similar in both groups. No differences in hepatic encephalopathy incidence were observed. OP failed to significantly decrease plasma ammonia at the given doses (10 g/day). Higher doses of OP might be required in Child-Pugh A and B patients. OP appeared well tolerated.
Grants:	Instituto de Salud Carlos III TRA-190 Ministerio de Economía y Competitividad FIS/10-1028
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Ammonia ; Cirrhosis ; Hepatic encephalopathy ; Ornithine phenylacetate ; Upper gastrointestinal bleeding
Published in:	Therapeutic Advances in Gastroenterology, Vol. 9 (july 2016) , p. 823-835, ISSN 1756-2848

DOI: 10.1177/1756283X16658252
PMID: 27803737

13 p, 895.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles